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Abstract
Background Ponesimod is a potent selective sphingosine-
1-phosphate receptor 1 (S1P1) modulator, which leads to a
reduction in circulating lymphocytes, reflecting their se-
questration within lymphoid organs. Modulation of the S1P1
receptor has been previously described to be an effective
treatment of autoimmune diseases (e.g., multiple sclerosis).
Objectives The aim of this study was to compare the
relative bioavailability of two polymorphic forms of
ponesimod in capsules (Form A versus Form C; Study 1)
and the relative bioavailability of a capsule formulation and
a tablet formulation (both polymorphic Form C; Study 2).
Methods Two open-label, randomized, two-way crossover
studies in healthy subjects were performed. In Study 1, 12
male subjects received a single dose of 20 mg of polymor-
phic Form A or Form C of ponesimod in a capsule. In Study
2, 14 male and female subjects (ratio 1:1) received a single
dose of 40 mg of polymorphic Form C of ponesimod in ei-
ther a capsule or a tablet formulation. Pharmacokinetic and
safety variables (clinical laboratory test results, vital signs,
and an electrocardiogram) were assessed.
Results Comparison of the exposure to ponesimod fol-
lowing administration of the formulations in Study 1
showed that the 90 % confidence intervals of the geometric
mean ratios for the area under the curve from time zero to
infinity (AUC0–inf), the area under the curve from time zero
to the time of the last measurable concentration (AUC0–t),
the terminal half-life (t), and the maximum plasma
concentration (Cmax) were all within the 0.80–1.25 bioe-
quivalence interval. In Study 2, more rapid absorption of
ponesimod was observed from the tablet formulation than
from the capsule formulation. There were no relevant dif-
ferences in the safety and tolerability profiles between the
different formulations.
Conclusion The two polymorphic forms of ponesimod
and tablet versus capsule formulations were similar in
terms of pharmacokinetics, safety, and tolerability.
Key Points
The pharmacokinetics of a single oral dose of two
polymorphic forms (Form A versus Form C) of
ponesimod in capsules and a tablet formulation
(Form C) were compared.
Comparison between the two polymorphic forms and
comparison between the capsule and tablet
formulations did not reveal relevant differences in
pharmacokinetic and safety properties.
Capsules can be substituted with tablets, from which
ponesimod is absorbed slightly more rapidly.
1 Introduction
Sphingosine-1-phosphate (S1P) is a phospholipid display-
ing a wide range of physiological roles [1–3]. S1P effects
are mediated by the activation of five G-protein-coupled
receptors, S1P1 to S1P5. Among them, the S1P1 receptors,
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which are expressed in many cell types (e.g., lymphocytes,
cardiomyocytes, and endothelial cells), induce Gai protein-
mediated signaling and play a role in the immune and
cardiovascular systems [4]. Recent studies have revealed
that functional antagonism of the S1P1 receptor leads to
inhibition of the egress of lymphocytes from secondary
lymphoid organs and a low lymphocyte count in peripheral
blood [5].
Ponesimod (ACT-128800) is a potent, orally active,
selective, reversible S1P1 receptor modulator [6] currently
in clinical development for the treatment of autoimmune
diseases and has successfully reached its study end points
in recent phase II trials in patients with chronic plaque
psoriasis [7] or relapsing–remitting multiple sclerosis [8].
Single- and multiple-dose administration of ponesimod
results in a dose-dependent decrease in circulating lym-
phocytes in healthy subjects and is associated with heart
rate reduction, a delay in atrioventricular conduction, and
pulmonary effects [9–13].
The maximum plasma concentration (Cmax) is achieved
approximately 2–4 h after dosing (tmax), and the terminal
half-life (t) is approximately 32 h. Steady-state conditions
are attained within 4–5 days when ponesimod is adminis-
tered once daily at any given dose. Increases in Cmax are
dose proportional, while increases in the area under the
curve (AUC) are slightly greater than dose proportional [9–
11]. A previous study [9] revealed low variability in
pharmacokinetic parameters (inter-subject variability
\36 %). Previous clinical trials were performed with
polymorph Form A (a hydrated crystalline form) of pone-
simod capsules. During the development of the drug, solid-
state investigations revealed the existence of distinct
polymorphic forms of ponesimod. Form C (an anhydrous
polymorphic form)—the thermodynamically most stable
form at room temperature so far known—was identified.
Moreover, a tablet formulation of Form C with a smaller
size, compared with the capsules, was developed.
The aim of this study was to compare the two poly-
morphic forms (Form A and Form C in capsules), as well
as the capsule and tablet formulations of Form C of
ponesimod, in terms of their pharmacokinetics, safety, and
tolerability, in order to bridge the results obtained in early




Healthy male and female subjects aged between 18 and
65 years were included in this study. The health of the
subjects was assessed at the screening visit, which included
recording of the medical history, medications taken during
the 3 months preceding the screening visit, a physical ex-
amination, measurement of body weight and height, clin-
ical laboratory tests, recording of vital signs, and a standard
electrocardiogram (ECG). Because of the teratogenic po-
tential of ponesimod, women of childbearing potential
were required to use two reliable and protocol-approved
methods of contraception from screening until 2 months
after the last study drug intake. At screening, subjects had
to have a PR interval of\200 ms, a heart rate of[55 beats
per minute (bpm), and a total lymphocyte count of[1000
lymphocytes/lL. Written informed consent was obtained
from each individual participating in the study prior to any
study procedure and after adequate explanation of the aims,
methods, objectives, and potential hazards of the studies.
These studies were conducted at different centers and at
different times. The Comite´ de Protection des Personnes
(Paris, France) approved the protocol of Study 1, and the
Aspire Institutional Review Board (La Mesa, CA, USA)
approved the protocol of Study 2. These studies were
performed according to good clinical practice and in ac-
cordance with the principles of the Declaration of Helsinki.
2.2 Study Design
This work was performed at two centers, one in France for
the comparison of polymorphic Form A and Form C in
capsules (Study 1) and one in the USA for the comparison
between capsules and tablets of Form C (Study 2). Each
study was a single-center, randomized, open-label, two-
period, two-treatment, crossover, biocomparison study. A
total of 26 subjects (12 healthy male subjects in Study 1:
age 31.3 [±12.8] years, body weight 75.4 [±11.3] kg; 14
healthy male and female subjects [ratio 1:1] in Study 2: age
31.1 [±14.9] years, body weight 69.0 [±14.5] kg) were
enrolled, and all subjects received active treatment. A
power of 80 % was estimated with a sample size of 12
subjects (in Study 1) and 14 subjects (in Study 2), based on
an intra-subject coefficient of variation of the tablet for-
mulation of *12 % observed in previous clinical trials of
ponesimod. The treatment consisted of two treatment pe-
riods of a single dose of ponesimod 20 mg as one Form A
or Form C capsule (in Study 1) or two treatment periods of
a single dose of ponesimod 40 mg either as one capsule or
one tablet (in Study 2). These doses have been used in
phase II trials [7, 8]. All treatments were administered in
the morning with approximately 240 mL of water, and the
two treatment periods were separated by a wash-out period
of 8–15 days in Study 1 and 14–15 days in Study 2. The
subjects remained fasted from at least 10 h prior to drug
intake until 4 h afterward. The subjects remained in the
clinic from day -1 (i.e., the day prior to study drug ad-
ministration) until day 2, 24 h after study drug
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administration, and they could then be discharged if this
was allowed on the basis of their medical condition at the
end of each treatment period. An end-of-study visit com-
prising the same examinations as those performed at the
screening visit was conducted 6 days or 22 (?2) days after
the last study drug administration in Study 1 and Study 2,
respectively.
2.3 Safety and Tolerability Assessments
Safety and tolerability were evaluated by monitoring of
adverse events and vital signs (supine blood pressure and
heart rate), a cardiodynamic assessment (a 12-lead ECG
recording), pulmonary function tests, clinical laboratory
tests, and physical and neurological examinations.
Vital signs were recorded from subjects in the supine
position after they had rested for at least a 5-min period
pre-dose and 1, 2.5, 4, 10, 24, 48, and 144 h after study
drug administration in both Study 1 and Study 2. In Study
1, vital signs were, in addition, recorded 0.5, 1.5, 6, 36, 72,
96, and 120 h after study drug administration. A standard
12-lead ECG was recorded at rest in the supine position
pre-dose and 1, 2.5, 4, 10, 24, 48, and 144 h after study
drug administration in both studies. Clinical laboratory
tests and a physical examination were done prior to study
drug administration and during the end-of-study visit.
2.4 Pharmacodynamic Assessments
A lymphocyte count was only performed pre-dose and
144 h after ponesimod administration in Study 2. Two
additional assessments (24 and 48 h after study drug ad-
ministration) were performed in Study 1.
2.5 Pharmacokinetic Assessments and Analysis
Blood samples of about 3 mL were collected in ethylene-
diaminetetraacetic acid (EDTA) tubes just before study
drug administration and 0.5, 1, 1.5, 2.5, 4, 6, 10, 16, 24, 36,
48, 72, 96, 120, and 144 h after study drug administration
in both Study 1 and Study 2. After centrifugation, plasma
was transferred into a labeled polypropylene tube and
stored at -21 C (±5 C) pending analysis. Plasma con-
centrations of ponesimod were determined using a
validated liquid chromatography–tandem mass spec-
trometry (LC–MS/MS) assay with a lower limit of quan-
tification of 1 ng/mL [9]. Analysis of quality-control
samples of all runs showed that the inter-day coefficients of
variation were \12.2 %, whereas the average intra-day
inaccuracy was in the range of -6.0 to 3.3 %. Noncom-
partmental pharmacokinetic analyses were performed using
Professional WinNonlin 6.1 software (Pharsight Corp.,
Mountain View, CA, USA). The variables Cmax and tmax
were directly read from the plasma concentration–time
profiles, AUC from time zero to the time of the last mea-
surable concentration (AUC0–t) was calculated using the
trapezoidal method [14], and t was calculated as ln 2/kz,
where kz is the terminal elimination rate constant estimated
by log-linear regression analysis. Pharmacokinetic vari-
ables were analyzed descriptively, providing geometric
means and 95 % confidence intervals (CIs) for Cmax, AUC
from time zero to infinity (AUC0–inf), AUC0–t (i.e., AUC
from time zero to 144 h [AUC0–144h]), and t. For tmax, the
median with minimum and maximum values were calcu-
lated and reported.
2.6 Statistical Analysis
Safety and tolerability data were analyzed descriptively.
Bioequivalence was explored, and the geometric mean
ratios of AUC and Cmax of Form C/Form A and
tablet/capsule, as well as their 90 % CIs, were derived from
mixed-effect models with treatment, sequence, and period
as fixed effects and subjects as random effects, and by a
linear model with treatment and subjects as fixed effects.
Differences in tmax were explored using the nonparametric
Wilcoxon signed-rank test.
SAS software versions 8.2 and 9.1 (SAS Institute,
Cary, NC, USA) were used for the statistical analysis and
the reporting of safety and tolerability data. For the phar-
macokinetics, the statistical package R (R Foundation for
Statistical Computing Version 2.6.1, lme function) was
used. Cardiodynamic and pharmacodynamic data are ex-
pressed as mean ± standard deviation (SD). The Student’s
t test was used to analyze the effects of ponesimod on the
heart rate and blood pressure. Differences were considered
to be statistically significant at p\ 0.05.
3 Results
3.1 Pharmacokinetics
In Study 1, the plasma concentration–time profiles of
ponesimod were characterized by a median tmax of 4 h for
both polymorphic forms in capsules (Fig. 1a; Table 1).
Table 1 reveals that following ponesimod 20 mg, the ob-
served total exposure, Cmax, and t were similar with Form
A and Form C. When bioequivalence was explored by
mixed-effect and linear models, the geometric mean ratios
(and 90 % CIs) of Cmax and AUC for Form C versus Form
A capsules were all within the 0.80–1.25 bioequivalence
interval (Fig. 2; Table 1).
In Study 2, subjects received ponesimod 40 mg as either
a tablet or a capsule of Form C. When both formulations
were compared, total exposure and t were similar
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(Table 1). Cmax was slightly higher and reached earlier
with the tablet than with the capsule (Fig. 1b; Table 1),
indicating more rapid absorption of ponesimod when ad-
ministered in the tablet formulation. The 90 % CIs of the
estimated geometric mean ratios of AUC0–t (AUC0–144h)
and AUC0–inf were contained within the 0.80–1.25 bioe-
quivalence interval. The estimated geometric mean ratio
for Cmax was 27 % higher (i.e., ratio 1.27) with the tablet
than with the capsule formulation (90 % CI 1.15–1.40),
and t tended to be slightly shorter with the tablet for-
mulation (ratio 0.90, 90 % CI 0.77–1.05) (Fig. 2).
In Study 2, both male and female subjects (ratio 1:1) were
enrolled. The observed Cmax was greater in female subjects
(geometric means [95 % CIs] 251.4 [176.6–357.8] ng/mL
and 326.8 [272.7–391.7] ng/mL for capsules and tablets,
respectively) than in male subjects (160.1 [127.2–201.7] ng/
Fig. 1 Arithmetic mean (with standard deviation) plasma concentra-
tion–time profiles of ponesimod (left graphs from 0 to 144 h [with
linear scales and semi-logarithmic scales shown as insets]; right
graphs from 0 to 8 h) in healthy subjects after a single dose of
a 20 mg as a Form A or Form C capsule (n = 12) or b 40 mg as a
Form C capsule or tablet (n = 14)
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mL and 199.4 [165.4–240.0] ng/mL for capsules and tablets,
respectively). Moreover, exposure to ponesimod (AUC0–inf)
was greater in female subjects (9841 [7292–13,280] ngh/mL
and 10,864 [8826–13,372] ngh/mL for capsules and tablets,
respectively) than in male subjects (6361 [4896–8264] ngh/
mL and 6543 [4947–8654] ngh/mL for capsules and tablets,
respectively), and t was slightly longer in female subjects
(37.1 [27.8–49.5] h and 31.2 [24.6–39.5] h for capsules and
tablets, respectively) than in male subjects (26.3 [23.2–29.7]
h and 25.2 [23.3–27.3] h for capsules and tablets,
respectively).
3.2 Safety and Tolerability
No serious or severe adverse events occurred during these
two studies. There was no marked difference in the nature,
severity, and incidence of adverse events reported for the
different formulations in Study 1 (Form A and Form C
capsules) and Study 2 (FormC capsule and tablet) (Table 2).
All reported adverse events were of mild to moderate in-
tensity, were considered by the investigators to be related to
the study drug, and were reported as being resolved by the
end of the studies. In both studies, the most frequently ob-
served adverse events were headache, dizziness, nausea, and
sinus bradycardia (defined as a heart rate below40 bpm), and
three subjects (one in Study 1 and two in Study 2) displayed
an event of first-degree atrioventricular block (defined as a
PR interval above 200 ms). When comparing Study 1 and
Study 2 (Table 2), the incidence of adverse events (i.e., the
number of subjects with at least one adverse event) was
higher following administration of ponesimod 40 mg
(85.7 %) than following ponesimod 20 mg (33.3 %).
In Study 1, maximum heart rate changes of (mean ± SD)
-20.2 ± 6.0 bpm (t = 9.2, p\ 0.001) and -18.8 ±
5.6 bpm (t = 10.7, p\ 0.001) 2.5 h after administration of
Form A and Form C, respectively, were observed (Fig. 3a).
There was no relevant difference between the two polymor-
phic forms of ponesimod (t = 0.6, p = 0.6).
In Study 2, the maximum heart rate changes were
(mean ± SD) -15.6 ± 10.6 bpm (t = 4.9, p\ 0.0001)
and -16.2 ± 6.4 bpm (t = 5.0, p\ 0.0001) 2.5 h after
Table 1 Comparison of pharmacokinetic parameters of the two polymorphic forms (Study 1) and the tablet versus capsule formulations (Study
2)
N Cmax (ng/mL) tmax (h)
a AUC0–t (ngh/mL) AUC0–inf (ngh/mL) t (h)
Study 1 (20 mg)
Form A 12 95.0 (82.0–110) 4.0 (2.5–6.0) 3006 (2718–3325) 3091 (2806–3404) 26.3 (23.6–29.4)
Form C 12 89.4 (70.7–113) 4.0 (2.5–10.0) 3064 (2649–3544) 3150 (2725–3641) 27.4 (25.1–29.9)
Form C versus Form Ab 12 0.94 (0.81–1.10) NC 1.02 (0.93–1.12) 1.02 (0.93–1.12) NC
Study 2 (40 mg)
Capsule 14 201 (160–251) 5.0 (2.5–16.0) 7542 (6122–9290) 7912 (6391–9795) 31.2 (26.4–36.9)
Tablet 14 255 (212–307) 4.0 (3.9–5.3) 8146 (6641–9991) 8431 (6821–10,421) 28.0 (24.8–31.7)
Tablet versus capsuleb 14 1.27 (1.15–1.40) NC 1.08 (0.96–1.22) 1.07 (0.95–1.19) 0.90 (0.77–1.05)
The data are expressed as geometric mean (95 % confidence interval), except where indicated otherwise
AUC0–inf area under the curve from time zero to infinity, AUC0–t area under the curve from time zero to the time of the last measurable
concentration, Cmax maximum plasma concentration, NC not calculated, t terminal half-life, tmax time to maximum plasma concentration
a The data are expressed as median (range)
b The data are expressed as geometric mean ratio (90 % confidence interval)
Fig. 2 Geometric mean ratios (with 90 % confidence intervals)
derived from mixed-effect models of the area under the curve from
time zero to the time of the last measurable concentration (AUC0–t),
the area under the curve from time zero to infinity (AUC0–inf), and the
maximum plasma concentration (Cmax) in Study 1 (comparison of the
two polymorphic Forms C and A; n = 12) and in Study 2
(comparison of the tablet and capsule formulations; n = 14). The
dotted lines represent the lower and upper bounds of the bioe-
quivalence interval (0.80–1.25)
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administration of the capsule and tablet formulations, re-
spectively (Fig. 3b). There was no relevant difference be-
tween the capsule and tablet formulations of Form C
(t = 0.2, p = 0.9) (Fig. 3b).
A reduction in blood pressure, compared with baseline,
following administration of both polymorphic forms of
ponesimod (20 mg) was observed. However, no relevant
differences were observed in the decrease in systolic and di-
astolic blood pressure between Form A (systolic: -7
± 11 mmHg; diastolic: -10 ± 7 mmHg) and Form C (sys-
tolic: -6 ± 14 mmHg, t = 0.2, p = 0.8; diastolic: -8
± 5 mmHg, t = 0.8, p = 0.4). In Study 2, both the capsule
(systolic:-7 ± 9 mmHg; diastolic:-9 ± 8 mmHg) and the
tablet (systolic: -6 ± 6 mmHg, t = 0.4, p = 0.7; diastolic:
-7 ± 11 mmHg, t = 0.7, p = 0.5) formulations triggered
similar decreases inbloodpressure. Themaximumdecrease in
blood pressure was observed 2.5 h after ponesimod admin-
istration in both Study 1 and Study 2.
In both studies, administration of ponesimod 20 or
40 mg did not alter other safety parameters, such as ECG
variables (including the QTcB and QTcF intervals) and
body weight. There were no marked differences regarding
the number of ECG abnormalities in Study 1 (three ECG
abnormalities were observed with each polymorphic form)
or Study 2 (16 and 20 abnormalities were observed with the
capsule and tablet, respectively). Thus, the frequency of
abnormalities was higher following administration of
ponesimod 40 mg than following ponesimod 20 mg.
As expected, a single administration of ponesimod
20 mg (mean ± SD decreases in the number of lympho-
cytes: -1.05 ± 0.50 9 109 cells/L and -0.95 ± 0.47
9 109 cells/L for Form A and Form C, respectively) or
40 mg (-0.30 ± 0.51 9 109 cells/L and -0.23 ± 0.27
9 109 cells/L for the capsule and tablet, respectively) led
to a reduction in the lymphocyte count (not shown). This
effect was not considered to be an adverse event, as it is an
anticipated pharmacodynamic effect of the drug.
4 Discussion
The aim of the present study was to compare two poly-
morphic capsule forms, as well as comparing tablet and
capsule formulations (of the same polymorphic form) of
ponesimod, a potent S1P1 modulator.
The capsule and tablet formulations of ponesimod have
similar concentration–time profiles and exposure, as well
as t values, though absorption of ponesimod from the
tablet formulation was slightly more rapid, with a higher
Cmax than that seen with the capsule formulation. The
observed safety profile was comparable between the dif-
ferent formulations. Previous clinical studies were per-
formed with ponesimod polymorphic Form A. This form is
a crystalline solid obtained by rapid precipitation, whereas
another formulation obtained by slow crystallization has
been developed. This Form C is thermodynamically more
stable than Form A. In addition, the slow crystallization of
Form C in the final step of the synthesis is easier to control
and more reproducible, especially on a large manufacturing
scale, than the rapid precipitation that yields Form A. In
addition, a tablet formulation has been developed, which is
preferred to the capsule formulation, since the tablets are
smaller and easier to swallow, which may improve patient
compliance. It is worth noting that difficulties in swal-
lowing are relatively frequent in patients with multiple
sclerosis [15]. More importantly, tablets are generally more
stable than capsules. In the present work, we have shown
bioequivalence between the two polymorphic forms of
ponesimod, and we observed slightly more rapid absorp-
tion of ponesimod when it was administered as tablet for-
mulation. Therefore, ponesimod capsules can be
substituted with tablets without any dose adjustment.
Between Study 1 and Study 2, the increases in Cmax
were dose proportional and the increases in AUC were
slightly greater than dose proportional, which is in line
with the findings of previous clinical studies performed
Table 2 Treatment-emergent
adverse events (AEs) in Study 1
and Study 2
Study 1 (20 mg) Study 2 (40 mg)
Form A Form C Capsule Tablet
Treatment
Number of subjects dosed 12 12 14 14
Number of subjects with at least one AE (%) 4 (33.3) 4 (33.3) 12 (85.7) 12 (85.7)
Total number of AEs 6 5 40 43
Number of subjects reporting an event (%)
Headache 2 (16.7) 1 (8.3) 4 (28.6) 6 (42.9)
Dizziness – – 9 (64.3) 7 (50.0)
Sinus bradycardia 2 (16.7) 1 (8.3) 6 (42.9) 6 (42.9)
First-degree atrioventricular block 1 (8.3) 1 (8.3) 1 (7.1) 1 (7.1)
Nausea 1 (8.3) 1 (8.3) 2 (14.3) 2 (14.3)
Vomiting – 1 (8.3) – 1 (7.1)
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with ponesimod [8–11]. Whereas similar exposure in male
and female subjects has been seen previously [10], the
findings of a recent study [11] are in good agreement with
the greater exposure in female subjects that was observed
in the present work. This finding could be related to dif-
ferences in body weight, requiring dose adjustment [16,
17].
In terms of safety and tolerability, a similar incidence
and nature of adverse events was observed in Study 1 and
Study 2. No new findings were observed, in comparison
with previous studies [7–13]. The incidence of adverse
events and the percentage of subjects displaying adverse
events were dose dependent. In current phase II studies, an
up-titration scheme (a first dose of 10 mg) is applied in
patients to improve the safety and tolerability of ponesimod
treatment [7, 8]. The lymphocyte nadir (maximum ob-
served decrease) was higher following administration of
ponesimod 20 mg than following 40 mg. This might have
been related to the timing of the assessments. Indeed, in
Study 2, the lymphocyte count was assessed pre-dose and
144 h after ponesimod administration. In Study 1, addi-
tional assessments were performed daily.
In good agreement with previous studies, we observed
transient significant reductions in the heart rate and blood
pressure following administration of ponesimod, which
were induced by the activation of S1P1 [18]. The maximum
decrease was observed 2.5 h after ponesimod administra-
tion, and the heart rate returned to baseline within 10 h, as
previously observed [9–11]. When comparing Study 1 and
Study 2, no clear dose-dependent effect was observed. This
was also the case in a previous study, in which the decrease
in the heart rate was similar in the 20 and 50 mg dose
groups [9]. While comparison across studies has limita-
tions, we may assume that the effect on the heart rate
reaches a plateau with ponesimod 20 mg. This reduction in
the heart rate following ponesimod administration is
Fig. 3 Arithmetic mean (with
standard deviation) heart rates
from 0 to 144 h after
administration of ponesimod at
a dose of a 20 mg (Study 1;
n = 12) or b 40 mg (Study 2;
n = 14) in healthy subjects. The
insets show the arithmetic mean
heart rates (with standard
deviations) from 0 to 10 h. bpm
beats per minute
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explained by the internalization of the S1P1 receptors and
their desensitization. This effect has been well character-
ized for S1P modulators [18–20].
5 Conclusion
The two polymorphic forms of ponesimod and the tablet
and capsule formulations were similar in terms of their
pharmacokinetics, except for more rapid absorption of the
tablet formulation than the capsule formulation. At the
same dose, the strength, safety, and tolerability were
similar. Therefore, Form A can be substituted with Form C,
and capsules can be substituted with tablets.
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